Coherus BioSciences acquires Surface Oncology and with it SRF 388 for lung and liver cancer and SFR 114 for solid tumours,
Coherus BioSciences, Inc. and Surface Oncology, Inc. announced that the companies have entered into a definitive merger agreement providing that, at the closing, Coherus will acquire Surface Oncology, a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment.
The Surface acquisition adds two differentiated clinical stage assets to Coherus’ novel I-O pipeline: SRF 388, a novel IL-27-targeted antibody currently being evaluated in Phase II clinical trials in lung cancer and liver cancer, and SFR 114, a CCR8-targeted antibody currently in a Phase 1/II study as a monotherapy in patients with advanced solid tumors. The transaction was unanimously approved by the boards of directors of both companies and is expected to close in the third quarter of 2023.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
